individual protocols will differ
Regulatory status: unapproved and research-use-only As of the preparation of this article, BPC-157 has not received marketing authorization from the US Food and Drug Administration, the European Medicines Agency, or equivalent national regulators for any therapeutic indication
Andrew: We were talking about coenzyme Q10 and the Kreb cycle, and I forgot to close the hatch on supplements more broadly
In den Gruppen 4, 5 und 6 wurde TRIS-BPC157 intramuskulr (i
Recommendations for use Bedoyecta tri is not intended for the intravenous route of administration, only for intramuscular administration
Male monotherapy: 2,000-3,000 IU 3x weekly